JIUYUAN GENE (02566) announced its interim results, with a net profit attributable to shareholders of the parent company amounting to 91.269 million yuan, representing a year-on-year increase of 1.21%.

JIUYUAN GENE (02566) announced its mid-2026 performance, with revenue of approximately 631 million yuan, a year-on-year decrease of 1.23%; net profit attributable to shareholders of the parent company was 91.269 million yuan, a year-on-year increase of 1.21%; earnings per share were 0.38 yuan. The announcement stated that the company's revenue saw a slight decline in the first half of the year, mainly due to multiple factors: first, the Ministry of Finance and the State Administration of Taxation issued a new policy No. 10 effective from January 2026, which adjusted the simple tax rate for ordinary biological products from 3% to 13%, leading to an overall increase in the company's actual tax burden; second, the deepening reform of DRG/DIP payment methods affected medical insurance's "bundled payment" model, pressuring hospitals to control costs, resulting in a decrease in average expenses per case; third, the company proactively enhanced its management of funds and accounts receivable, further reducing the scale of notes and optimizing the accounts receivable turnover period, with some orders being sacrificed for cash quality, leading to a slightly downward revenue trend prioritizing cash flow. During the reporting period, thanks to the company's high-quality product supply capability and cost advantages, its two products that have undergone centralized procurement, Jiao Ting and Yi Nuo Jia, successfully completed their contract renewals; in addition, the products Jixinfen and Jilixin, which were launched last year, maintained a rapid growth rate in sales volume during the reporting period.